January 17, 2025

MedPAC Provider Recs Likely to Be Ignored in Favor of Savings Targets Like Site Neutrality, Medicaid, Rule Repeals

By Beth Steindecker

We doubt Medicare Payment Advisory Commission’s (MedPAC) FY/CY26 Medicare payment recommendations for home health agencies, inpatient rehab facilities, skilled nursing facilities, hospices, dialysis centers, hospitals, and physician offices, which were voted on Thursday in nearly…

Read More >>

January 16, 2025

FY25 Defense Spending Iis Likely to Come in Above Our Expectations

By Joe Lieber

Our long-held belief has been that defense spending for FY25 would clock in at ~$920 billion; however, that figure seems too low in our view, given the recent news flow.  We now believe defense spending…

Read More >>

January 16, 2025

UNH: Though Confident, Public Policy Questions Remain

By Beth Steindecker

UnitedHealth’s (UNH) comments during its 4Q and full year 2024 earnings call about changes its it taking to head off certain public policy concerns (PBMs, prior authorization/claim denials) seem like the company is in catch-up…

Read More >>

January 15, 2025

(DKNG, FLUT, CZR, MGM) Sports Betting Policy Update

By Joe Lieber

We see little positive legislative movement for the sports gambling sector [DKNG, FLUT, CZR, MGM], since we do not expect any of the 11 states that have yet to legalize the practice to make further…

Read More >>

January 14, 2025

[CVS, CI, UNH]: FTC 2nd (Negative) Report on PBMs Doesn’t Change Overhang Trajectory

By Beth Steindecker

The FTC’s unanimously-supported release of its second interim report on pharmacy benefit managers (PBMs), focused on specialty drug dispensing at affiliated pharmacies [CVS, CI, UNH] that generated an extra $7.3B in revenue over six years,…

Read More >>

January 13, 2025

Medtronic: Medicare RDN Coverage in 4Q24

By John Leppard

In keeping with expectations laid out in our note late last week, CMS’s opening of a National Coverage Analysis (NCA) for renal denervation (RDN) [Medtronic (MDT), Otsuka (4578.JT) / ReCor] this afternoon has a target…

Read More >>

January 13, 2025

Inspire V Payment & Coverage Quick Take

By John Leppard

INSP’s disclosure today that physicians will likely be billing its Inspire V device procedures under CPT 64568 ($596) during a “transition period” – rather than existing Inspire IV code CPT 64582 ($816), as we had…

Read More >>

January 13, 2025

Capitol Policy Weekly: Jan. 13-17

By Joe Lieber

This week starts a host of hearings on President-elect Trump’s cabinet nominees (see below). The Senate is also expected to pass an immigration bill, the Laken Riley Act (S. 5), which would require the Dept….

Read More >>

January 12, 2025

Diagnostics’ New Supreme Court Risk

By John Leppard

The Supreme Court’s (SCOTUS) decision on Friday to hear oral arguments in Becerra v. Braidwood, presumably in late March / early April, will likely serve as an overhang for screening test manufacturers [EXAS, GH, MYGN,…

Read More >>

January 11, 2025

[HUM, UNH, CVS, ELV, ALHC] CY26 Medicare Advantage Rates: Likely Upswing in the Final

By Beth Steindecker

CMS’s Friday release of the CY26 Advance Notice (AN) for Medicare Advantage (MA) insurers [HUM, UNH, CVS, ELV, ALHC, CLOV, CNC] came in better than our net YoY benchmark expectations with a proposed net increase…

Read More >>

January 10, 2025

Medtronic (MDT): Renal Denervation Coverage Read-Through?

By John Leppard

This morning’s opening of a Medicare National Coverage Determination (NCD) for privately-held Impulse Dynamics’ Optimizer System bolsters our view that coverage for renal denervation (RDN) systems [Medtronic (MDT), Otsuka / ReCor (4578.JT)] is unlikely to…

Read More >>

January 10, 2025

2025 Tax Primer: Extending the Trump Tax Provision et al.

By Joe Lieber

We continue to believe that Congress is likely to pass a massive $5 trillion- plus tax bill that would extend the 2017 Trump tax cuts, known as the Tax Cut and Jobs Act (TCJA). We…

Read More >>

January 8, 2025

Conference Policy Prep Pack: Healthcare Providers & Insurers

By Beth Steindecker

With a handful of healthcare provider and insurance companies headed to San Francisco next week for a key investor conference, below we provide a set of significant policy-related questions we would like to see management teams address…

Read More >>

January 8, 2025

Exact Sciences (EXAS): Cologuard Plus Coverage Questions

By John Leppard

A Jan. 1 update to CMS’s colorectal cancer (CRC) screening guide appears to support our view that Medicare coverage of EXAS’ Cologuard Plus (0464U: $592) and its 16% rate premium over the legacy version (81528:…

Read More >>

January 6, 2025

Conference Policy Prep Pack: Devices, Diagnostics, & Tools

By John Leppard

With medical device, equipment, diagnostics, and life science tools (LST) companies set to descend on San Francisco next week for a key investor conference, below we provide a set of significant policy-related questions for clients…

Read More >>